4.5 Review

Cardioprotection by adiponectin

Journal

TRENDS IN CARDIOVASCULAR MEDICINE
Volume 16, Issue 5, Pages 141-146

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2006.03.001

Keywords

-

Funding

  1. NHLBI NIH HHS [R01 HL077774-02, P01 HL081587, R01 HL077774, P01 HL081587-02, HL 77774, HL 81587] Funding Source: Medline
  2. NIAMS NIH HHS [R01 AR040197-14, AR 40197, R01 AR040197] Funding Source: Medline
  3. NIA NIH HHS [AG 15052, R01 AG015052-03, R01 AG015052, R37 AG015052] Funding Source: Medline

Ask authors/readers for more resources

Obesity-related disorders are closely associated with the pathogenesis of cardiovascular disease. Adiponectin is a circulating adipose tissue-derived hormone that is down-regulated in obese individuals. Hypoadiponectinemia has been identified as an independent risk factor for type 2 diabetes, coronary artery disease, and hypertension, and experimental studies show that adiponectin plays a protective role in the development of insulin resistance, atherosclerosis, and inflammation. More recent findings have shown that adiponectin directly affects signaling in myocardial cells and exerts beneficial actions on the heart after pressure overload and ischemia-reperfusion injury. This review focuses on the role of adiponectin in the regulation of myocardial remodeling and acute cardiac injury.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available